Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500916PMID: 29999975
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 330942-05-7
Drug Levels and Effects
Summary of Use during Lactation
Betrixaban is no longer marketed in the United States. Because no information is available on the use of betrixaban during breastfeeding and the drug is orally absorbable, an alternate drug is preferred, especially while nursing a newborn or preterm infant.[1,2]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Acenocoumarol, Dalteparin, Enoxaparin, Heparin, Rivaroxaban, Warfarin
References
- 1.
- Vanassche T, Vandenbriele C, Peerlinck K, et al. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Expert Opin Pharmacother. 2015;16:645–58. [PubMed: 25554350]
- 2.
- Cohen H, Arachchillage DR, Beyer-Westendorf J, et al. Direct oral anticoagulants and women. Semin Thromb Hemost. 2016;42:789–97. [PubMed: 27706531]
Substance Identification
Substance Name
Betrixaban
CAS Registry Number
330942-05-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Anticoagulants
Antithrombins
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.